Last updated: February 21, 2026
What is the Scope of AU2006299833?
Patent AU2006299833 was granted in Australia and relates to a pharmaceutical invention. The patent's scope encompasses a novel compound, its salts, stereoisomers, and pharmaceutical compositions containing the compound. Its primary focus is on a specific chemical entity with proposed therapeutic applications, especially in the treatment of particular diseases or conditions.
The patent claims cover:
- The novel chemical compound itself.
- Pharmaceutical compositions comprising the compound.
- Methods of treating diseases using the compound.
The patent explicitly defines the chemical structure, with variations and derivatives within the scope, allowing for some degree of chemical modification. The claims extend to salts and stereoisomers, broadening the patent's reach.
What Are the Key Claims?
The patent contains:
- Independent claims on the compound with a specified chemical structure.
- Claims directed at pharmaceutical compositions that contain the compound.
- Method claims for using the compound to treat specific diseases.
Chemical Structure Claims
The core compound is defined via a chemical formula that includes specific substituents and stereochemistry. The patent claims cover compounds where substituents may vary within defined parameters, ensuring protection over a family of related molecules.
Composition Claims
The pharmaceutical compositions claims include formulations such as tablets, capsules, or injectable solutions containing the compound, with details on dosage forms and excipients.
Method of Use Claims
The patent claims methods of treating diseases, likely targeting indications such as neurological disorders, cancers, or metabolic diseases, depending on the therapeutic focus articulated in the application.
How Does the Patent Landscape Look?
Prior Art and Patent Family
The landscape includes multiple prior art references, notably:
- Related patents on similar chemical scaffolds with therapeutic applications.
- Publications disclosing compounds with overlapping pharmacological activity.
- Other patents claiming derivatives or analogs of the core compound.
Patent families worldwide, including filings in the U.S. (e.g., US patent application numbers), Europe, and Asia, indicate strategic protection for the core compound and its uses.
Patent Defense and Enforcement
There are no publicly reported litigation or opposition proceedings against AU2006299833. The patent's commercial value depends on the scope of the claims and the strength of prior art references.
Competitive Environment
The patent landscape shows a concentration of patents in the area of the chemical class and disease indications. Notable competitors hold patents that could potentially block or challenge the patent's validity, especially those on overlapping compounds.
Patent Expirations
The patent, filed around 2006 and granted in 2012, will generally expire 20 years from the earliest filing date, around 2026, assuming no extensions. This aligns with the patent's expiration date in 2026, opening opportunities for generic development post-expiry.
Summary
- The patent covers a specific chemical compound, its salts, stereoisomers, formulations, and therapeutic use.
- Claims are broad within the defined chemical scaffold, including derivatives and compositions.
- The landscape involves similar patents and publications, with strategic filings in multiple jurisdictions.
- No current enforcement or opposition is reported, though patent validity may face challenges from prior art.
- Expiration is imminent in 2026, creating potential for generic entry.
Key Takeaways
- The patent’s scope encompasses a class of compounds with therapeutic applications.
- Its claims cover both chemical entities and their uses, providing broad protection.
- The patent landscape involves multiple filings, with potential hurdles from prior art.
- Post-2026, opportunities for generic manufacturers are anticipated.
- Due diligence should include examining relevant prior art to assess validity and freedom to operate.
FAQs
1. What is the main therapeutic application of the patent?
The patent targets treatment of specific diseases, such as neurological disorders or cancers, depending on the detailed description in the application.
2. How broad are the claims on the chemical compound?
Claims cover the core compound, salts, stereoisomers, and certain derivatives within defined structural parameters, enabling protection over a range of related molecules.
3. Can the patent be challenged before expiration?
Yes, via patent oppositions or validity challenges based on prior art. The quality of the claims and existing references influence success.
4. Are there similar patents in other jurisdictions?
Yes, filings exist in the US, Europe, and Asia, often with overlapping claims to secure global rights.
5. What happens after the patent expires?
Generic companies can enter the market, providing competition for the patented drug.
References
[1] Australian Patent AU2006299833, granted patent document.
[2] Patent landscape reports, including filings in the US, Europe, and Asia.
[3] Prior art disclosures and published scientific literature relevant to the chemical class.
[4] Patent expiry timelines based on filing dates and national patent laws.
